Welcome to the supplement, Vinflunine and Areas for Improvement in the Management of Urothelial Carcinoma, accompanying the winter 2013 edition of European Oncology & Haematology. The supplement includes five insightful review articles focusing on vinflunine in the management of urothelial carcinoma. This particular malignancy is a worthy focus for the supplement as there has been no improvement in survival rates over the past few decades and therapeutic options are limited. The expert authors provide enlightening and thought-provoking articles for our perusal. Please enjoy the knowledgeable content and we welcome your feedback.
Overview of Registration Trials Data in Urothelial Carcinoma In total, 450 patients were treated in two phase II trials and one phase III trial that together formed the basis for the registration of vinflunine monotherapy in urothelial carcinoma patients after failure of platinum-based therapy (see Table 1).1–3 Similar data were reported in the two phase […]
The potential role of vinflunine in sequential treatment strategies for urothelial carcinoma, in both the perioperative setting and maintenance therapy, will be highlighted below. Rationale for Perioperative Systematic Therapy in Bladder Cancer The natural history and evolution of urothelial carcinoma suggests that the study of perioperative systemic therapy may yield benefits (see Table 1),1–9 because […]
Standard Chemotherapy in ‘Fit’ Bladder Cancer Patients First-line treatment options in ‘fit’ bladder cancer patients who are able to receive platinum-based therapy include GC, paclitaxel/gemcitabine/cisplatin (PGC), methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) with or without granulocyte colony-stimulating factor (G-CSF), or high-dose (HD)-MVAC with G-CSF. The highest level of evidence and grade of recommendation is available […]
First-line Treatment of Unfit Bladder Cancer Patients – An Overview In the first-line setting treatment of unfit bladder cancer patients, a long list of small phase I, II and III trials investigating various combinations of chemotherapy regimens is available (see Table 1). Most data are on gemcitabine-based combinations, such as GCa, which is probably the […]
An overview of evidence on use and development of cytotoxic and targeted agents in the second-line setting after failure of a platinum-based regimen will be presented below. Additional considerations on the possible role of immunotherapy in bladder cancer are also discussed. Combinations of vinflunine with therapeutic agents that are already in use in bladder cancer […]
Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Urothelial carcinoma (UC) is the 11th most common cancer in the UK, with approximately 11,000 new bladder cancer diagnoses annually.1 Globally, bladder cancer accounts for approximately 635,000 new diagnoses and 228,000 deaths annually, based on the latest GLOBOCAN estimates for 2024.2 Bladder cancer constitutes the vast majority of urothelial malignancies (90–95%), with upper tract urothelial […]
2
Journal Archive
Comprising articles contributed by renowned thought leaders, European Oncology & Haematology is a peer reviewed, free-to-access, bi-annual journal that aims to disseminate best practice through review articles addressing the most important and salient developments in the Oncological & Haematology field in practical terms.
European Oncology & Haematology
Frequency: Two print issues per year (Summer & Winter); ePub ahead of print throughout the year.
Print ISSN: 2045-5275 Electronic ISSN: 2045-5283
Indexing: EMBASE, Google Scholar, Genamics JournalSeek
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
